[{"id":"31f0020c-0510-41ca-b50a-168b2e6ddd86","acronym":"","url":"https://clinicaltrials.gov/study/NCT03087071","created_at":"2021-01-18T15:12:32.712Z","updated_at":"2024-07-02T16:35:25.486Z","phase":"Phase 2","brief_title":"Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer","source_id_and_acronym":"NCT03087071","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • NRAS • MAP2K1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type","tags":["KRAS • BRAF • NRAS • MAP2K1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Vectibix (panitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/29/2017","start_date":" 12/29/2017","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2023-12-21"}]